
Please try another search
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
David S. Grayzel | 56 | 2017 | Independent Director |
Brian L. Kotzin | 74 | - | Scientific Advisor |
Sven Ante Lundberg | 61 | 2017 | Independent Director |
Isaac Manke | 47 | 2020 | Independent Director |
Kathleen D. LaPorte | 62 | 2021 | Independent Director |
Mary T. Thistle | 64 | 2024 | Independent Director |
Simon Read | 52 | 2022 | Scientific Advisor |
Michael Holers | - | - | Scientific Advisor |
John P. Atkinson | - | - | Scientific Advisor |
Diyong Xu | 42 | 2020 | Independent Director |
Arthur O. Tzianabos | 61 | 2024 | Director |
Peter A. Merkel | - | - | Scientific Advisor |
Mark T. Iwicki | 58 | 2024 | Independent Director |
Jodie Pope Morrison | 49 | 2024 | CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review